The Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market is expected to witness market growth of 10.7% CAGR during the forecast period (2022-2028).
Preimplantation genetic testing is increasingly being utilized by healthcare practitioners and institutions to identify problems present in embryos before implantation, as it has been shown to be an effective approach for diagnosing genetic disorders. Thus, in the next years, the demand for preimplantation genetic testing will be fueled by the need for better diagnostic methods to combat the increased prevalence of genetic diseases in babies.
Because of the rising number of cases with genetically imbalanced structures observed in children and neonates, preimplantation genetic diagnosis is considered a critical process. Preimplantation genetic diagnosis entails examining an embryo for a specific genetic condition before it implants. PGD is used to ensure that embryos that are not affected by the condition can return to the uterus. The PGD allows researchers to examine the DNA of eggs or embryos in order to select those with specific mutations for hereditary illnesses. When there are early chromosomal or genetic problems in the family, as well as in the context of in vitro fertilization programs, preimplantation genetic diagnostics are useful.
Before a reproductive clinic in Western Australia can generate embryos for PGD, it must first get authorisation from the WA Reproductive Technology Council (Council). This is to ensure that embryo testing is only done when there is a significant chance of a serious genetic problem (rather than for other reasons such as sex selection of embryos, which is illegal in Australia) and that patients have received proper genetic counseling. The Council examines the danger and severity of the condition, the test's safety and reliability, and the condition's impact on both the prospective child and the family before reaching a decision about PGD.
Developing countries such as China and India are participating in a number of reproductive health improvements, which have been supported by the introduction of a number of supportive government legislations.
The China Market dominated the Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $12,387 Thousands by 2028. The Japan Market is poised to grow at a CAGR of 10.1% during (2022-2028). Additionally, The India Market is expected to display a CAGR of 11.4% during (2022-2028).
Based on Test Type, the Market is segmented into Aneuploidy, Chromosomal Abnormalities, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Illumina, Inc., Invitae Corporation, Natera, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, PacGenomics, CeGaT GmbH, and Laboratory Corporation of America Holdings.
By Test Type
By Country
Preimplantation genetic testing is increasingly being utilized by healthcare practitioners and institutions to identify problems present in embryos before implantation, as it has been shown to be an effective approach for diagnosing genetic disorders. Thus, in the next years, the demand for preimplantation genetic testing will be fueled by the need for better diagnostic methods to combat the increased prevalence of genetic diseases in babies.
Because of the rising number of cases with genetically imbalanced structures observed in children and neonates, preimplantation genetic diagnosis is considered a critical process. Preimplantation genetic diagnosis entails examining an embryo for a specific genetic condition before it implants. PGD is used to ensure that embryos that are not affected by the condition can return to the uterus. The PGD allows researchers to examine the DNA of eggs or embryos in order to select those with specific mutations for hereditary illnesses. When there are early chromosomal or genetic problems in the family, as well as in the context of in vitro fertilization programs, preimplantation genetic diagnostics are useful.
Before a reproductive clinic in Western Australia can generate embryos for PGD, it must first get authorisation from the WA Reproductive Technology Council (Council). This is to ensure that embryo testing is only done when there is a significant chance of a serious genetic problem (rather than for other reasons such as sex selection of embryos, which is illegal in Australia) and that patients have received proper genetic counseling. The Council examines the danger and severity of the condition, the test's safety and reliability, and the condition's impact on both the prospective child and the family before reaching a decision about PGD.
Developing countries such as China and India are participating in a number of reproductive health improvements, which have been supported by the introduction of a number of supportive government legislations.
The China Market dominated the Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $12,387 Thousands by 2028. The Japan Market is poised to grow at a CAGR of 10.1% during (2022-2028). Additionally, The India Market is expected to display a CAGR of 11.4% during (2022-2028).
Based on Test Type, the Market is segmented into Aneuploidy, Chromosomal Abnormalities, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Illumina, Inc., Invitae Corporation, Natera, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, PacGenomics, CeGaT GmbH, and Laboratory Corporation of America Holdings.
Scope of the Study
Market Segments Covered in the Report:
By Test Type
- Aneuploidy
- Chromosomal Abnormalities
- X-linked diseases
- Single Gene Disorders
- HLA Typing
- Gender selection
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Illumina, Inc.
- Invitae Corporation
- Natera, Inc.
- Agilent Technologies, Inc.
- PerkinElmer, Inc.
- Quest Diagnostics Incorporated
- Reproductive Genetic Innovations
- PacGenomics
- CeGaT GmbH
- Laboratory Corporation of America Holdings
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market by Test Type
Chapter 4. Asia Pacific Preimplantation Genetics Diagnosis (PGD) Market by Country
Chapter 5. Company Profiles
Companies Mentioned
- Illumina, Inc.
- Invitae Corporation
- Natera, Inc.
- Agilent Technologies, Inc.
- PerkinElmer, Inc.
- Quest Diagnostics Incorporated
- Reproductive Genetic Innovations
- PacGenomics
- CeGaT GmbH
- Laboratory Corporation of America Holdings
Methodology
LOADING...
